Suven Life Sciences Limited (SUVEN) - Net Assets

Latest as of September 2025: Rs2.81 Billion INR ≈ $30.42 Million USD

Based on the latest financial reports, Suven Life Sciences Limited (SUVEN) has net assets worth Rs2.81 Billion INR (≈ $30.42 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs3.37 Billion ≈ $36.49 Million USD) and total liabilities (Rs561.36 Million ≈ $6.07 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SUVEN asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs2.81 Billion
% of Total Assets	83.36%
Annual Growth Rate	1.53%
5-Year Change	1.83%
10-Year Change	-81.53%
Growth Volatility	73.46

Suven Life Sciences Limited - Net Assets Trend (2005–2025)

This chart illustrates how Suven Life Sciences Limited's net assets have evolved over time, based on quarterly financial data. Also explore SUVEN total assets for the complete picture of this company's asset base.

Annual Net Assets for Suven Life Sciences Limited (2005–2025)

The table below shows the annual net assets of Suven Life Sciences Limited from 2005 to 2025. For live valuation and market cap data, see Suven Life Sciences Limited market capitalisation.

Year	Net Assets	Change
2025-03-31	Rs1.10 Billion ≈ $11.89 Million	-59.27%
2024-03-31	Rs2.70 Billion ≈ $29.20 Million	-28.05%
2023-03-31	Rs3.75 Billion ≈ $40.59 Million	+290.37%
2022-03-31	Rs961.45 Million ≈ $10.40 Million	-10.98%
2021-03-31	Rs1.08 Billion ≈ $11.68 Million	-24.66%
2020-03-31	Rs1.43 Billion ≈ $15.50 Million	-82.75%
2019-03-31	Rs8.31 Billion ≈ $89.87 Million	+8.29%
2018-03-31	Rs7.67 Billion ≈ $82.99 Million	+15.05%
2017-03-31	Rs6.67 Billion ≈ $72.13 Million	+12.01%
2016-03-31	Rs5.95 Billion ≈ $64.40 Million	+6.46%
2015-03-31	Rs5.59 Billion ≈ $60.49 Million	+111.50%
2014-03-31	Rs2.64 Billion ≈ $28.60 Million	+71.21%
2013-03-31	Rs1.54 Billion ≈ $16.70 Million	+21.12%
2012-03-31	Rs1.28 Billion ≈ $13.79 Million	+0.62%
2011-03-31	Rs1.27 Billion ≈ $13.71 Million	+7.35%
2010-03-31	Rs1.18 Billion ≈ $12.77 Million	+3.17%
2009-03-31	Rs1.14 Billion ≈ $12.38 Million	+7.57%
2008-03-31	Rs1.06 Billion ≈ $11.51 Million	+4.80%
2007-03-31	Rs1.02 Billion ≈ $10.98 Million	+12.53%
2006-03-31	Rs902.12 Million ≈ $9.76 Million	+11.12%
2005-03-31	Rs811.85 Million ≈ $8.78 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Suven Life Sciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 600180054900.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Common Stock	Rs218.07 Million	19.83%
Other Comprehensive Income	Rs420.71 Million	38.25%
Other Components	Rs6.47 Billion	588.05%
Total Equity	Rs1.10 Billion	100.00%

Suven Life Sciences Limited Competitors by Market Cap

The table below lists competitors of Suven Life Sciences Limited ranked by their market capitalization.

Company	Market Cap
Nanjing Zhongbei Group Co Ltd SHE:000421	$532.07 Million
Zhongbai Holdings Group Co Ltd SHE:000759	$532.20 Million
Guangdong Tecsun Science & Technology Co Ltd SHE:002908	$532.20 Million
CapitaLand Malaysia Mall Trust KLSE:5180	$532.26 Million
KT Submarine Co. Ltd KQ:060370	$531.40 Million
Shanghai Shen Lian Biomedical Corp SHG:688098	$531.20 Million
Diversified Royalty Corp TO:DIV	$531.11 Million
Hualan Group Co Ltd SHE:301027	$531.10 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Suven Life Sciences Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 2,700,406,000 to 1,099,868,000, a change of -1,600,538,000 (-59.3%).
Net loss of 1,607,450,000 reduced equity.
Other comprehensive income increased equity by 7,511,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs-1.61 Billion	-146.15%
Other Comprehensive Income	Rs7.51 Million	+0.68%
Other Changes	Rs-599.00K	-0.05%
Total Change	Rs-	-59.27%

Book Value vs Market Value Analysis

This analysis compares Suven Life Sciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 42.10x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 41.29x to 42.10x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2005-03-31	Rs5.13	Rs211.88	x
2006-03-31	Rs5.70	Rs211.88	x
2007-03-31	Rs6.42	Rs211.88	x
2008-03-31	Rs6.72	Rs211.88	x
2009-03-31	Rs7.23	Rs211.88	x
2010-03-31	Rs7.46	Rs211.88	x
2011-03-31	Rs8.01	Rs211.88	x
2012-03-31	Rs8.06	Rs211.88	x
2013-03-31	Rs9.76	Rs211.88	x
2014-03-31	Rs16.71	Rs211.88	x
2015-03-31	Rs35.35	Rs211.88	x
2016-03-31	Rs37.63	Rs211.88	x
2017-03-31	Rs42.16	Rs211.88	x
2018-03-31	Rs55.56	Rs211.88	x
2019-03-31	Rs60.16	Rs211.88	x
2020-03-31	Rs9.06	Rs211.88	x
2021-03-31	Rs6.83	Rs211.88	x
2022-03-31	Rs6.08	Rs211.88	x
2023-03-31	Rs23.72	Rs211.88	x
2024-03-31	Rs12.38	Rs211.88	x
2025-03-31	Rs5.03	Rs211.88	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Suven Life Sciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -146.15%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -2415.11%
• Asset Turnover: 0.05x
• Equity Multiplier: 1.23x
Recent ROE (-146.15%) is below the historical average (-12.89%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2005	2.96%	3.63%	0.49x	1.67x	Rs-57.12 Million
2006	7.08%	7.09%	0.63x	1.59x	Rs-26.34 Million
2007	11.10%	9.95%	0.65x	1.71x	Rs11.12 Million
2008	7.85%	6.96%	0.60x	1.87x	Rs-22.86 Million
2009	6.22%	5.06%	0.76x	1.63x	Rs-43.22 Million
2010	5.93%	5.41%	0.63x	1.73x	Rs-48.05 Million
2011	8.21%	6.91%	0.67x	1.76x	Rs-22.74 Million
2012	11.26%	7.03%	0.72x	2.23x	Rs16.10 Million
2013	19.97%	11.96%	0.77x	2.16x	Rs153.94 Million
2014	54.51%	28.25%	1.05x	1.84x	Rs1.18 Billion
2015	19.44%	20.88%	0.67x	1.38x	Rs528.19 Million
2016	11.21%	13.36%	0.64x	1.32x	Rs71.93 Million
2017	13.07%	16.04%	0.67x	1.22x	Rs204.87 Million
2018	16.12%	20.19%	0.67x	1.19x	Rs469.47 Million
2019	10.46%	13.47%	0.62x	1.25x	Rs38.44 Million
2020	-65.73%	-653.62%	0.08x	1.27x	Rs-1.09 Billion
2021	-66.80%	-535.31%	0.10x	1.19x	Rs-829.52 Million
2022	-126.89%	-1029.99%	0.11x	1.12x	Rs-1.32 Billion
2023	-31.51%	-873.52%	0.03x	1.04x	Rs-1.56 Billion
2024	-38.91%	-898.63%	0.04x	1.06x	Rs-1.32 Billion
2025	-146.15%	-2415.11%	0.05x	1.23x	Rs-1.72 Billion

Industry Comparison

This section compares Suven Life Sciences Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $23,713,303,062
Average return on equity (ROE) among peers: 8.81%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Suven Life Sciences Limited (SUVEN)	Rs2.81 Billion	2.96%	0.20x	$531.49 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$988.60 Million	6.59%	1.36x	$27.93 Million
Aarti Drugs Limited (AARTIDRUGS)	$6.52 Billion	21.67%	1.42x	$371.43 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$19.90 Billion	13.69%	0.46x	$725.68 Million
Abbott India Limited (ABBOTINDIA)	$36.99 Billion	32.48%	0.40x	$5.85 Billion
Ajanta Pharma Limited (AJANTPHARM)	$1.16 Billion	12.69%	1.32x	$3.81 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$6.25 Billion	-40.39%	3.91x	$906.19 Million
Alkem Laboratories Limited (ALKEM)	$88.47 Billion	18.60%	0.59x	$6.98 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.46 Billion	16.82%	0.29x	$178.52 Million
Alembic Pharmaceuticals Limited (APLLTD)	$51.90 Billion	11.24%	0.50x	$1.60 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$23.50 Billion	-5.26%	1.65x	$8.73 Billion

About Suven Life Sciences Limited

NSE:SUVEN India Drug Manufacturers - Specialty & Generic

Market Cap

$531.49 Million

Rs49.15 Billion INR

Market Cap Rank

#12221 Global

#574 in India

Share Price

Rs211.88

Change (1 day)

-2.51%

52-Week Range

Rs126.65 - Rs296.60

All Time High

Rs296.60